High CD155 expression by tumor cells was associated with PD-1+ CD8+T cells and poor response to anti-PD-1, and CD155+PD-L1− tumors exhibited a poor response to anti-PD-1/CTLA-4 therapy [59]. This evidence concerns the gene CTLA4 and neoplasm.